Diabetes Treatment Failure May Actually Be Nonadherence

Share this content:
Diabetes Treatment Failure May Actually Be Nonadherence
Diabetes Treatment Failure May Actually Be Nonadherence

FRIDAY, Sept. 22, 2017 (HealthDay News) -- Apparent diabetes treatment failures may in fact be attributable to nonadherence, according to a study published online Sept. 15 in Diabetes Care.

Yi-Ju Tseng, Ph.D., from Boston Children's Hospital, and colleagues retrospectively analyzed unidentifiable member claims data from 52,544 individuals covered by Aetna who had two physician claims or one hospitalization with a type 2 diabetes diagnosis (2010 to 2015).

The researchers found that of 22,956 patients given second-line treatment, only 8.2 percent had evidence of recommended use of metformin in the prior 60 days, and 28.0 percent had no prior claims evidence of having taken metformin. Only 49.5 percent of patients could have had recommended use. An additional second-line antihyperglycemic medication or insulin was more likely in patients given their initial second-line medication without evidence of recommended use of metformin (P < 0.001).

"Despite published guidelines, second-line therapy often is initiated without evidence of recommended use of first-line therapy. Apparent treatment failures, which may in fact be attributable to nonadherence to guidelines, are common," the authors write. "Point-of-care and population-level processes are needed to monitor and improve guideline adherence."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »